Granite Investment Partners’s Axsome Therapeutics AXSM Stock Holding History

Granite Investment Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6M	Sell	80,124 -175	-0.2%	-$38K	1%	20
2026 Q1	$13.6M	Sell	80,299 -4,595	-5%	-$794K	0.83%	29
2025 Q4	$15.5M	Sell	84,894 -3,664	-4%	-$512K	0.92%	24
2025 Q3	$10.8M	Sell	88,558 -39,968	-31%	-$4.5M	0.61%	59
2025 Q2	$13.4M	Sell	128,526 -10,193	-7%	-$1.08M	0.65%	56
2025 Q1	$16.2M	Buy	138,719 +47,070	+51%	+$5.36M	0.82%	41
2024 Q4	$7.75M	Buy	+91,649	New	+$8.43M	0.34%	98

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Granite Investment Partners's AXSM Position: Q2 2026 in Review

Granite Investment Partners reduced its Axsome Therapeutics (AXSM) stake by 0.22% in Q2 2026, selling an estimated $38K and leaving 80,124 shares worth $19.6M. The position accounts for 1% of the portfolio, ranked #20.

Granite Investment Partners first reported a position in AXSM in Q4 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Granite Investment Partners held 80,124 shares of Axsome Therapeutics worth $19.6M as of Q2 2026.
Granite Investment Partners sold 175 Axsome Therapeutics shares in Q2 2026, an estimated $38K.
Axsome Therapeutics made up 1% of Granite Investment Partners's portfolio in Q2 2026, its #20 holding.
Granite Investment Partners first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 7 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Granite Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.